Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials
European Archives of Oto-Rhino-Laryngology · 2024
DOI: 10.1007/s00405-024-08768-w ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2024. Verfasst von Shuangyue Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit nennt 29 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region, the Research Foundation of the Health Department of Guangxi Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Immune checkpoint inhibitor (ICI) monotherapy and chemotherapy (CT) have been used to treat recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC), with demonstrated survival benefits and good safety. However, whether combination therapy is superior to CT alone remains unclear. We summarized the existing evidence comparing the effectiveness and toxicities of ICI combined with CT versus CT alone. METHODS: Online databases was conducted for eligible randomized controlled trials (RCTs) published up to November 1, 2023. Progression-free survival (PFS) and overall survival (OS) were the primary endpoint. Objective response rates (ORRs) and adverse events (AEs) were the secondary endpoint. RESULTS: Three randomized controlled trials (Capture-1st, JUPITER-02, and RATIONALE-309) were included. First-line ICI therapy combined with CT showed significant improvement in PFS (hazard ratio[HR], 0.53; 95% confidence interval[CI]: 0.44-0.64), OS (HR, 0.63;95%CI: 0.49-0.81) and ORRs (odds ratio[OR], 1.79;95%CI: 1.30-2.46), when compared with CT alone. AEs ≥ grade 3 during treatment and treatment-related deaths were not significantly different between the two groups. CONCLUSIONS: In patients with R/M-NPC, ICI therapy combined with CT showed improved ORRs, PFS, and OS, with similar safety as CT alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
- Guangxi Tumor Radiation Therapy Clinical Medical Research Center, Nanning, 530021, Guangxi, China.
- Guangxi Key Laboratory of Immunology and Metabolism for Liver Diseases, Nanning, 530021, Guangxi, China.
- Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning, 530021, Guangxi, China.
- Department of Oncology, The 923 Hospital of People's Liberation Army, Nanning, 530021, Guangxi, China.
- Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. kangmin@gxmu.edu.cn.
Förderung
- the National Natural Science Foundation of China
- Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region
- the Research Foundation of the Health Department of Guangxi Province
- Guangxi Medical University Training Program for Distinguished Young Scholars
- Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University
- Guangxi Overseas High-level Talent "Hundred People Program"
- Guangxi Overseas High‐level Talent “Hundred People Program”
Zitieren
APA
Wang, S., Huang, X., Li, R., Zhou, Z., & Kang, M. (2024). Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08768-w
Vancouver
Wang S, Huang X, Li R, Zhou Z, Kang M. Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials. European Archives of Oto-Rhino-Laryngology. 2024. doi:10.1007/s00405-024-08768-w
BibTeX
@article{Wang2024,
author = {Wang, Shuangyue and Huang, Xiaojie and Li, Rong and Zhou, Ziyan and Kang, Min},
title = {Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2024},
doi = {10.1007/s00405-024-08768-w}
}
EUVIMED